{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:12Z","timestamp":1790821932565,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40259-021-00492-9","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T20:04:36Z","timestamp":1626984276000},"page":"563-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product"],"prefix":"10.1007","volume":"35","author":[{"given":"Katariina M.","family":"Hutterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-5686","authenticated-orcid":false,"given":"Scott","family":"Kuhns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9965","authenticated-orcid":false,"given":"Shawn","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-0962","authenticated-orcid":false,"given":"Mats","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-9586","authenticated-orcid":false,"given":"Jennifer","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"492_CR1","unstructured":"Soliris\u00ae (eculizumab RP) Injection, for intravenous use. Prescribing information. Alexion Pharmaceuticals, Inc. 2019. https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf. Accessed 7 July 2020."},{"key":"492_CR2","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.jacc.2017.02.058","volume":"69","author":"MT Corban","year":"2017","unstructured":"Corban MT, Duarte-Garcia A, McBane RD, Matteson EL, Lerman LO, Lerman A. Role of vascular endothelial cells and implications for risk stratification and targeted therapies. J Am Coll Cardiol. 2017;69:2317\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"492_CR3","unstructured":"Soliris. Summary of product characteristics. European Medicines Agency. 2020 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed 7 July 2020."},{"key":"492_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40259-018-0319-9","volume":"32","author":"VG Dhara","year":"2018","unstructured":"Dhara VG, Naik HM, Majewska NI, Betenbauch MJ. Recombinant antibody production in CHO and NS0 cells: differences and similarities. BioDrugs. 2018;32:571\u201384.","journal-title":"BioDrugs"},{"key":"492_CR5","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products (revision 1). 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 12 Nov 2020."},{"key":"492_CR6","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en.pdf. Accessed 11 Feb 2021."},{"key":"492_CR7","unstructured":"U.S. Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf. Accessed 12 Nov 2020."},{"key":"492_CR8","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. 2015. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm291134.pdf. Accessed 12 Nov 2020."},{"key":"492_CR9","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1002\/jps.22695","volume":"100","author":"CH Li","year":"2011","unstructured":"Li CH, Nguyen X, Narhi L, Chemmalil L, Towers E, Muzammil S, et al. Applications of circular dichroism (CD) for structural analysis of proteins: qualification of near- and far-UV CD for protein higher order structural analysis. J Pharm Sci. 2011;100:4642\u201354.","journal-title":"J Pharm Sci"},{"issue":"3","key":"492_CR10","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0006-3495(00)76713-0","volume":"78","author":"P Schuck","year":"2000","unstructured":"Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J. 2000;78(3):1606\u201319.","journal-title":"Biophys J"},{"key":"492_CR11","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. Guidance for Industry. 2019. https:\/\/www.fda.gov\/media\/125484\/download. Accessed 6 May 2021."},{"key":"492_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1074\/jbc.M709987200","volume":"283","author":"J Wypych","year":"2008","unstructured":"Wypych J, Li M, Guo A, Zhang Z, Martinex T, Allen MJ, et al. Human IgG2 antibodies display disulfide-mediate structural isoforms. J Biol Chem. 2008;283:1619\u201325.","journal-title":"J Biol Chem"},{"key":"492_CR13","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1002\/jps.22695","volume":"100","author":"CH Li","year":"2011","unstructured":"Li CH, Nguyen X, Narhi L, Chemmalil L, Towers E, Muzammil S, et al. Applications of circular dichroism (CD) for structural analysis of proteins. J Pharm Sci. 2011;100:4642\u201354.","journal-title":"J Pharm Sci"},{"key":"492_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.xphs.2019.10.026","volume":"109","author":"J Wen","year":"2020","unstructured":"Wen J, Batabyal D, Knutson N, Lord H, Wikstr\u00f6m MA. Comparison between emerging and current biophysical methods for the assessment of higher-order structure of biopharmaceuticals. J Pharm Sci. 2020;109:247\u201353.","journal-title":"J Pharm Sci"},{"key":"492_CR15","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1021\/acs.analchem.9b05385","volume":"92","author":"KW Eliott","year":"2020","unstructured":"Eliott KW, Ghasriani H, Wikstr\u00f6m M, Giddens JP, Aubin Y, Delaglio F, et al. Comparative analysis of one-dimensional protein fingerprint by line shape enhancement and two-dimensional 1H,13C methyl NMR methods for characterization of the higher order structure of IgG1 monoclonal antibodies. Anal Chem. 2020;92:6366\u201373.","journal-title":"Anal Chem"},{"key":"492_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/19420862.2018.1544454","volume":"11","author":"RG Brinson","year":"2019","unstructured":"Brinson RG, Marino JP, Delaglio F, Arbogast LW, Evans RM, Kearsley A, et al. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. MAbs. 2019;11:94\u2013105.","journal-title":"MAbs"},{"key":"492_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ymeth.2018.04.011","volume":"144","author":"D Goswami","year":"2018","unstructured":"Goswami D, Zhang J, Bondarenko PV, Zhang Z. MS-based conformation analysis of recombinant proteins in design, optimization and development of biopharmaceuticals. Methods. 2018;144:134\u201351.","journal-title":"Methods"},{"key":"492_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1517\/14712598.7.9.1401","volume":"7","author":"R Jefferis","year":"2007","unstructured":"Jefferis R. Antibody therapeutics: isotype and glycoform selection. Exp Opin Biol Ther. 2007;7:1401\u201313.","journal-title":"Exp Opin Biol Ther."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00492-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-021-00492-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00492-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T03:51:04Z","timestamp":1633924264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-021-00492-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s40259-021-00492-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"20 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees and stockholders of Amgen Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals. All laboratory health and safety procedures have been complied with in the course of conducting this experimental work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"KH: Led study design and assessment plan; authored the similarity plan; contributed to data interpretation, manuscript development, and review. AI: Contributed to study design and assessment plan; data acquisition, analysis, and interpretation; manuscript development. SK: Contributed to method development and testing; data analysis and interpretation; manuscript development. SC: Contributed to study design and assessment plan; protocol\/methods development, data acquisition, analysis, and interpretation; manuscript development. MW: Contributed to study design and assessment plan; data acquisition, analysis, and interpretation; manuscript development. JL: Contributed to study design and assessment plan; development and authoring of manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}